Scott Kopetz
Scott Kopetz
University of Texas MD Anderson Cancer Center
E-mail megerősítve itt: - Kezdőlap
Hivatkozott rá
Hivatkozott rá
The consensus molecular subtypes of colorectal cancer
J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ...
Nature medicine 21 (11), 1350-1356, 2015
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ...
Journal of clinical oncology 27 (22), 3677, 2009
Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours
J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ...
The Journal of pathology 232 (2), 199-209, 2014
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
Cancer classification using the Immunoscore: a worldwide task force
J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ...
Journal of translational medicine 10 (1), 1-10, 2012
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ...
Cancer 117 (20), 4623-4632, 2011
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
DG Blazer III, Y Kishi, DM Maru, S Kopetz, YS Chun, MJ Overman, ...
Journal of Clinical Oncology 26 (33), 5344-5351, 2008
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
R Dienstmann, L Vermeulen, J Guinney, S Kopetz, S Tejpar, J Tabernero
Nature reviews cancer 17 (2), 79-92, 2017
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032, 2015
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ...
New England Journal of Medicine 381 (17), 1632-1643, 2019
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests
RFA Logan, J Patnick, C Nickerson, L Coleman, MD Rutter, ...
Gut 61 (10), 1439-1446, 2012
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
YS Chun, JN Vauthey, P Boonsirikamchai, DM Maru, S Kopetz, ...
Jama 302 (21), 2338-2344, 2009
Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for …
AR Sepulveda, SR Hamilton, CJ Allegra, W Grody, AM Cushman-Vokoun, ...
American journal of clinical pathology 147 (3), 221-260, 2017
Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600–mutant colorectal cancer
RB Corcoran, CE Atreya, GS Falchook, EL Kwak, DP Ryan, JC Bendell, ...
Journal of clinical oncology 33 (34), 4023, 2015
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
A Brouquet, EK Abdalla, S Kopetz, CR Garrett, MJ Overman, C Eng, ...
Journal of clinical oncology 29 (8), 1083, 2011
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy
Y Kishi, S Kopetz, YS Chun, M Palavecino, EK Abdalla, JN Vauthey
Annals of surgical oncology 16 (3), 614-622, 2009
Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials
F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ...
Journal of clinical oncology 33 (25), 2753, 2015
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20